Please login to the form below

Not currently logged in
Email:
Password:

Astellas bolsters oncology clinical development leadership

Dr Steven Benner joins while Dr Anne Keating is promoted

Astellas has expanded its oncology clinical development leadership team at its Northbrook, Illinois site in the US with the appointments of Dr Steven Benner and Dr Anne Keating.

Dr Benner joins the Japanese pharmaceutical firm as senior vice president and therapeutic area head for oncology, with a remit to oversee Astellas' global oncology development, which includes clinical programmes in breast cancer, leukaemia, lung cancer and prostate cancer.

He brings senior leadership experience in clinical development, compliance and licensing from Bristol-Myers Squibb, Cell Therapeutics, OncoMed Pharmaceuticals and PDL BioPharma, as well as academic experience from the University of North Carolina's Chapel Hill School of Medicine and the University of Texas MD Anderson Cancer Center.

Meanwhile, Dr Keating becomes vice president of clinical science for oncology within Astellas' Development organisation.

In her new role, Dr Keating will be responsible for the leadership and strategic direction of all phases of the company's global clinical science oncology programmes, and will drive operational best practice in the design and execution of projects across the unit's portfolio.

She first joined Astellas in 2004 as director of clinical operations and most recently served as an executive director and global development project leader for oncology, during which time she oversaw the clinical development programme for Astellas' NSCLC candidate, ASP8273.

Dr Bernhardt Zeiher, president of Development at Astellas, said: "Astellas couldn't be more pleased to have Steven and Anne help lead us on our journey to becoming a global oncology leader.

"They have diverse experience across all areas of development and I know they will provide the strategic oversight to help us continue to address the evolving needs of our patients."

17th October 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics